Positron emission tomography with lipid metabolism markers for primary liver cancers imaging
Authors:
Ľudovít Lukáč 1; Branislav Kunčák 2; Marika Vereb 3; Lucia Kaliská 4; Soňa Balogová 5,6
Authors‘ workplace:
I. Interná klinika LF UK a UNB, Bratislava
1; Interné oddelenie, Nemocnica Nové Zámky
2; Nuklearmedizin, Kassel, Nemecko
3; INMM, Banská Bystrica
4; Klinika nukleárnej medicíny LF UK a OÚSA, Bratislava
5; Klinika nukleárnej medicíny nemocnice Tenon AP-HP a Univerzity Pierre et Marie Curie, Paríž, Francúzsko
6
Published in:
NuklMed 2014;3:22-30
Category:
Review Article
Overview
Accurate staging of HCC has a significant impact on patient management. 18F-fluorodeoxyglucose (FDG) has limitations in the functional imaging of liver tumours, in particular the detection rate of intra-hepatic well-differentiated hepatocellular carcinoma (HCC) is low. To overcome this lack of sensitivity, choline PET tracers have proposed: 11C-choline or its analogues 18F-fluorocholine (FCH) and 18F-fluoroethylcholine (FEC). They showed sensitivity compatible with an accurate staging of well-differentiated HCC and also of intermediate or poorly differentiated HCC. Actually dual tracer PET with FDG and a lipid tracer has the best performance, as some lesions in a given patients may be of a different aggressiveness and take-up only one tracer. In this aim, visualisation of HCC tumours with FDG is pejorative, whereas visualisation with a lipid tracer was indicative of a better prognosis in pilot studies. Some evidence has also been brought that the detection of distant metastasis benefit from a dual tracer approach.
Among non-HCC liver malignancies in adults, only cholangiocarcinoma has been reported to take up lipid tracers in small series; FCH uptake has been reported in a child with recurrent hepatoblastoma. Concerning benign liver tumours, adenoma is rarely visible on choline PET, whereas focal nodular hyperplasia (FNH) is visible as a hot focus in the majority of cases. To characterize a liver nodule as HCC, this uptake by FNH may be seen as a source of false-positive results. FCH could be helpful to differentiate in difficult cases between FNH and hepatocellular adenoma which has the potential to degenerate.
Key Words:
choline, PET, FCH, liver tumour, hepatocellular carcinoma, focal nodular hyperplasia, hepatoblastoma
Sources
1. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma. Hepatology 2005;42:1208–1236
2. Bennett GL, Krinsky GA, Abitbol RJ et al. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR 2002;179:75–80
3. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699
4. Yu NC, Chaudhari V, Raman SS et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in pa tients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:161–167
5. Snowberger N, Chinnakotla S, Lepe RM et al. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther 2007;26:1187–1194
6. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430
7. Mazzaferro V, Bhoori S, Sposito C et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 (S2):S44–57
8. Larsson P, Arvidsson D, Björnstedt M et al. Adding 11C-acetate to 18F-FDG at PET examination has an incremental value in the diagnosis of hepatocellular carcinoma. Mol Imaging Radionucl Ther 2012;21:6–12
9. Enomoto K, Fukunaga T, Okazumi S et al. Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma? Kaku Igaku 1991;28:1353–1356
10. Delbeke D, Martin WH, Sandler MP et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510–515
11. Trojan J, Schroeder O, Raedle J et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314–3319
12. Khan MA, Combs CS, Brunt EM et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792–797
13. Teefey SA, Hildeboldt CC, Dehdashti F et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003;226:533–542
14. Wudel LJ Jr, Delbeke D, Morris D et al. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117–124
15. Boursier J, Aubé C, Pilette C et al. Coexistence d’un carcinome hépato-cellulaire et d’une métastase hépatique. Intérêt de la tomodensitométrie par émission de positrons dans les tumeurs du foie. Radiol 2006;87:1708–1710
16. Yoon KT, Kim JK, Kim do Y et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007;72(S1):104–110
17. Lee JE, Jang JY, Jeong SW et al. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. World J Gastroenterol 2012;18:2979–2987
18. Sugiyama M, Sakahara H, Torizuka T et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004;39:961–968
19. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocelluar carcinoma and other liver masses. J Nucl Med 2003;44:213–221
20. Ho CL, Chen S, Yeung DW et al. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007;48:902–910
21. Ho CL, Chen S, Cheng TK et al. PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology 2011;258:515–523
22. Cheung TT, Chan SC, Ho CL et al. Can positron emission tomography with the dual tracers [11C]acetate and [18F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl 2011;17:1218–1225
23. Park JW, Kim JH, Kim SK et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49:1912–1921
24. Lindhe O, Sun A, Ulin J et al. [18F]Fluoroacetate is not a functional analogue of [11C]acetate in normal physiology. Eur J Nucl Med Mol Imaging 2009;36:1453–1459
25. Ho CL, Cheung MK, Chen S et al. [18F]fluoroacetate positron emission tomography for hepatocellular carcinoma and metastases: an alternative tracer for [11C]acetate? Mol Imaging 2012;11:229–239
26. Li CW, Kuo YC, Chen CY et al. Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T. Magn Reson Med 2005;53:770–776
27. Salem N, Kuang Y, Wang F et al. PET imaging of hepatocellular carcinoma with 2-deoxy-2[18F]fluoro-D-glucose, 6-deoxy-6[18F] fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. Q J Nucl Med Mol Imaging 2009;53:144–156
28. Kuang Y, Salem N, Tian H et al. Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11c]choline: correlation with in vivo metabolic studies. J Nucl Med 2011;521:98–106
29. Kolthammer JA, Corn DJ, Tenley N et al. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging 2011;38:1248–1256
30. Talbot JN, Gutman F, Fartoux L et al. PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006;33:1285–1289
31. Talbot JN, Fartoux L, Balogova S et al. Detection of hepatocellular carcinoma with PET/CT: A prospective comparison of 18F-Fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010;51:1699–1706
32. Peng H, Levin CS. Study of PET intrinsic spatial resolution and contrast recovery improvement for PET/MRI systems. Phys Med Biol 2012;57:N101–115
33. Treglia G, Giovannini E, Di Franco D et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012;26:451–461
34. Balogova S, Bumsel F, Kerrou K et al. La fluorocholine (18F) a une utilité clinique dans le cancer de la prostate et le carcinome hépatocellulaire.parfois chez le même malade. Méd Nucl 2010,34:378–382
35. Yamamoto Y, Nishiyama Y, Kameyama R et al. Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med 2008;49:1245–1248
36. Wu HB, Wang QS, Li BY et al. 18F-FDG in conjunction with 11C-choline PET/CT in the diagnosis of hepatocellular carcinoma. Clin Nucl Med 2011;36:1092–1097
37. Cheung TT, Ho CL, Lo CM et al. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon‘s perspective. J Nucl Med 2013;54:192–200
38. Shiomi S, Nishiguchi S, Ishizu H et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96:1877–1880
39. Hatano E, Ikai I, Higashi T et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006;30:1736–1741
40. Seo S, Hatano E, Higashi T et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13:427–433
41. Ahn SG, Kim SH, Jeon TJ et al. The role of preoperative [18F] fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg 2011;15:2044–2052
42. Kitamura K, Hatano E, Higashi T et al. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol 2012;19:156–162
43. Yang SH, Suh KS, Lee HW et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655–1660
44. Lee JW, Paeng JC, Kang KW et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009;50:682–687
45. Kornberg A, Freesmeyer M, Bärthel E et al. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009;9:592–600
46. Kornberg A, Küpper B, Tannapfel A et al. Patients with 18F-FDG non-avid advanced HCC on clinical staging may achieve recurrence-free long-term survival after liver transplantation. Liver Transpl 2012;18:53–61
47. Kim BK, Kang WJ, Kim JK et al. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer 2011;117:4779–4787
48. Song MJ, Bae SH, Yoo IeR et al. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012;18:3215–3222
49. Kucuk ON, Soydal C, Araz M. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. Clin Nucl Med 2013;38:e283–289
50. Fartoux L, Balogova S, Nataf V et al. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nucl Med Commun 2012;33:757–765
51. Torizuka T, Tamaki N, Inokuma T et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965–1969
52. Anderson GS, Brinkmann F, Soulen MC et al. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192–197
53. Chen YK, Hsieh DS, Liao CS et al. Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 2005;25:4719–4725
54. Risse JH, Pauleit D, Bender H et al. 18F-FDG-PET and histopathology in 131I-lipiodol treatment for primary liver cancer. Cancer Biother Radiopharm 2009;24:445–452
55. Sun L, Guan YS, Pan WM et al. Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT. World J Hepatol 2009;1:90–97
56. Bieze M, van Gulik TM, Bennink R. Hepatoblastoma evaluated by 18F-fluoromethyl choline PET/CT. Clin Nucl Med 2013;38:e80–82
57. van den Esschert JW, Bieze M, Beuers UH et al. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging 2011;38:436–440
58. Bieze M, Bennink RJ, El-Massoudi Y et al. The use of 18F-fluoromethylcholine PET/CT in differentiating focal nodular hyperplasia from hepatocellular adenoma: a prospective study of diagnostic accuracy. Nucl Med Commun 2013;34:146–154
59. Roivainen A, Naum A, Nuutinen H et al. Characterization of hepatic tumors using [11C]metomidate through positron emission tomography: comparison with [11C] acetate. EJNMMI Res 2013;3:13
60. Magini G, Farsad M, Frigerio M et al. C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med 2009;34:659–665
61. Dokmak S, Paradis V, Vilgrain V et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009;137:1698–1705
62. Stoot JH, Coelen RJ, De Jong MC et al. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB 2010;12:509–522
Labels
Nuclear medicine Radiodiagnostics RadiotherapyArticle was published in
Nuclear Medicine
2014 Issue 2
Most read in this issue
- Evaluation of the effectiveness of radioiodine ablation for differentiated thyroid carcinoma
- Positron emission tomography with lipid metabolism markers for primary liver cancers imaging